Boston ScientificBSXEarnings & Financial Report
Boston Scientific Corporation (BSC) is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Revenue
$4.1B
Gross Profit
$2.9B
Operating Profit
$520.0M
Net Profit
$322.0M
Gross Margin
69.2%
Operating Margin
12.6%
Net Margin
7.8%
YoY Growth
14.5%
EPS
$0.22
Boston Scientific Q2 FY2024 Financial Summary
Boston Scientific reported revenue of $4.1B (up 14.5% YoY) for Q2 FY2024, with a net profit of $322.0M (up 19.3% YoY) (7.8% margin). Cost of goods sold was $1.3B, operating expenses totaled $2.3B.
Key Financial Metrics
| Total Revenue | $4.1B |
|---|---|
| Net Profit | $322.0M |
| Gross Margin | 69.2% |
| Operating Margin | 12.6% |
| Report Period | Q2 FY2024 |
Revenue Breakdown
Boston Scientific Q2 FY2024 revenue of $4.1B breaks down across 6 segments, led by Cardiovascular at $2.6B (63.9% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Cardiovascular | $2.6B | 63.9% |
| Global Urologyand Pelvic Health Reporting Unit | $363.0M | 8.8% |
| Cardiac Rhythm Management | $352.0M | 8.5% |
| Watchman | $342.0M | 8.3% |
| Electrophysiology EP | $271.0M | 6.6% |
| Interventional Cardiology Therapies | $201.0M | 4.9% |
Boston Scientific Revenue by Segment — Quarterly Trend
Boston Scientific revenue by segment across the last 4 reported quarters, showing how each business line (such as Cardiovascular and Global Urologyand Pelvic Health Reporting Unit) has evolved quarter over quarter.
| Segment | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 |
|---|---|---|---|---|
| Cardiovascular | $3.5B | $3.5B | — | — |
| Global Urologyand Pelvic Health Reporting Unit | — | $521.0M | $511.0M | $499.0M |
| Cardiac Rhythm Management | — | — | $354.0M | $355.0M |
| Watchman | — | $485.0M | $470.0M | $446.0M |
| Electrophysiology EP | — | $606.0M | $607.0M | $587.0M |
Boston Scientific Annual Revenue by Year
Boston Scientific annual revenue history includes year-by-year totals (for example, 2025 revenue was $20.1B).
| Year | Annual Revenue |
|---|---|
| 2025 | $20.1B |
| 2024 | $16.7B |
Boston Scientific Quarterly Revenue & Net Profit History
Boston Scientific results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $5.2B | +11.6% | $1.3B | 25.7% |
| Q4 FY2025 | $5.3B | +15.8% | $670.0M | 12.7% |
| Q3 FY2025 | $5.1B | +20.3% | $755.0M | 14.9% |
| Q2 FY2025 | $5.1B | +22.8% | $795.0M | 15.7% |
| Q1 FY2025 | $4.7B | +20.9% | $672.0M | 14.4% |
| Q4 FY2024 | $4.6B | +22.5% | $563.0M | 12.3% |
| Q3 FY2024 | $4.2B | +19.3% | $468.0M | 11.1% |
| Q2 FY2024 | $4.1B | +14.5% | $322.0M | 7.8% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.12B | $4.21B | $4.56B | $4.66B | $5.06B | $5.07B | $5.29B | $5.20B |
| YoY Growth | 14.5% | 19.3% | 22.5% | 20.9% | 22.8% | 20.3% | 15.8% | 11.6% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $37.11B | $38.08B | $39.40B | $40.14B | $41.56B | $42.71B | $43.67B | N/A |
| Liabilities | $16.74B | $17.37B | $17.63B | $17.93B | $19.14B | $19.31B | $19.44B | N/A |
| Equity | $20.37B | $20.71B | $21.77B | $22.21B | $22.42B | $23.39B | $24.23B | N/A |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $813.0M | $1.00B | $1.46B | $541.0M | $1.29B | $1.34B | $1.36B |